X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (147) 147
humans (121) 121
male (94) 94
female (83) 83
middle aged (77) 77
arginine - analogs & derivatives (72) 72
aged (61) 61
nitric oxide (60) 60
arginine - blood (58) 58
adult (46) 46
arginine (43) 43
asymmetric dimethylarginine (39) 39
cardiac & cardiovascular systems (38) 38
l-arginine (38) 38
risk factors (38) 38
animals (36) 36
mortality (36) 36
oxidative stress (34) 34
adma (33) 33
peripheral vascular disease (32) 32
endothelium (31) 31
biomarkers - blood (28) 28
endothelial dysfunction (28) 28
nitric-oxide synthase (27) 27
plasma (26) 26
atherosclerosis (24) 24
cardiovascular disease (24) 24
disease (24) 24
research (24) 24
hypertension (23) 23
nitric-oxide (23) 23
mice (22) 22
analysis (19) 19
physiological aspects (19) 19
cardiovascular (18) 18
cardiovascular diseases (18) 18
mass spectrometry (18) 18
arginine - metabolism (17) 17
homoarginine (17) 17
prospective studies (17) 17
abridged index medicus (16) 16
prognosis (16) 16
risk (16) 16
biochemistry & molecular biology (15) 15
coronary-artery-disease (15) 15
asymmetric dimethylarginine adma (14) 14
biomarkers (14) 14
nitric oxide - metabolism (14) 14
stroke (14) 14
cardiovascular risk (13) 13
care and treatment (13) 13
double-blind method (13) 13
dysfunction (13) 13
isoprostanes (13) 13
medical laboratory technology (13) 13
nitric oxide synthase - antagonists & inhibitors (13) 13
symmetric dimethylarginine (13) 13
aged, 80 and over (12) 12
blood pressure (12) 12
cardiology (12) 12
cardiovascular-disease (12) 12
case-control studies (12) 12
coronary heart disease (12) 12
endothelial function (12) 12
health aspects (12) 12
hematology (12) 12
pharmacology & pharmacy (12) 12
risk-factor (12) 12
sdma (12) 12
tandem mass spectrometry (12) 12
article (11) 11
diabetes (11) 11
dinoprost - analogs & derivatives (11) 11
heart (11) 11
homoarginine - blood (11) 11
inflammation (11) 11
mass-spectrometric determination (11) 11
biochemical research methods (10) 10
c-reactive protein (10) 10
cardiac patients (10) 10
chemistry, analytical (10) 10
cohort studies (10) 10
cross-sectional studies (10) 10
endocrinology & metabolism (10) 10
epidemiology (10) 10
heart-failure (10) 10
medical research (10) 10
proportional hazards models (10) 10
prostaglandins (10) 10
amidohydrolases - genetics (9) 9
dimethylaminohydrolase (9) 9
dinoprost - urine (9) 9
dose-response relationship, drug (9) 9
endogenous inhibitor (9) 9
endothelium, vascular - physiopathology (9) 9
gas chromatography-mass spectrometry - methods (9) 9
hypercholesterolemia (9) 9
inhibitor (9) 9
l-homoarginine (9) 9
low-density-lipoprotein (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Scientific Reports, ISSN 2045-2322, 12/2019, Volume 9, Issue 1, pp. 1 - 6
The purpose of the present study was to assess whether 6-week ranolazine application on top of guideline-based treatment impacts on the arginine/NO pathway and... 
Urine | Myocardial infarction | Creatinine | Oxidative stress | Heart attacks | Arginine | Ischemia | Plasma levels | Angina | Angina pectoris | Patients
Journal Article
PLoS ONE, ISSN 1932-6203, 08/2017, Volume 12, Issue 8, pp. e0182427 - e0182427
Background Sepsis is defined as a dysregulated immune response to infection. Impaired immune response in sepsis, often described as endotoxin tolerance, is... 
WHOLE-BLOOD | PROGNOSIS | IMMUNOPARALYSIS | MULTIDISCIPLINARY SCIENCES | SEPTIC SHOCK | NECROSIS-FACTOR-ALPHA | CYTOKINE RELEASE | OPTIONS | HUMAN MONOCYTES | SEVERITY | REVERSAL | Biomarkers - metabolism | Sepsis - immunology | Prospective Studies | Humans | Middle Aged | Sepsis - diagnosis | Male | Monocytes - metabolism | Monocytes - immunology | Case-Control Studies | HLA-DR alpha-Chains - metabolism | Monocytes - drug effects | Sepsis - drug therapy | Tumor Necrosis Factor-alpha - pharmacology | Immunosuppression | Immune Tolerance - immunology | Sepsis - metabolism | Lipopolysaccharides - pharmacology | Female | Aged | Intervention | Flow cytometry | Intensive care | Critical care | Stimulation | Infections | Blood | Lipopolysaccharides | Surgical instruments | Proteins | Biological effects | Immunology | Surgery | Peripheral blood | Direct reduction | Tumor necrosis factor-TNF | Target groups | Immune system | Antigens | Immune response | Cytokines | Mortality | Septic shock | Inflammation | Gene expression | Ribonucleic acid--RNA | Patients | Immunological tolerance | Medicine | Polymerase chain reaction | Cytometry | Monocytes | Tumor necrosis factor | Diagnostic software | Biomarkers | Sepsis | Histocompatibility antigen HLA | Diagnostic systems | Anesthesiology | Index Medicus | Immune systems | Ribonucleic acids
Journal Article
American Heart Journal, ISSN 0002-8703, 2015, Volume 176, pp. 100 - 106
Journal Article
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, ISSN 1590-1874, 09/2019, pp. 1 - 5
Guanidino compounds, including asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), and L-homoarginine (hArg), have been associated with... 
Stroke | Ischemia | Neurological complications | Mortality | Index Medicus
Journal Article
Nephrology Dialysis Transplantation, ISSN 0931-0509, 10/2008, Volume 23, Issue 10, pp. 3174 - 3183
Background. Renin-angiotensin system blockade reduces proteinuria and prevents nephropathy progression in patients with type 2 diabetes mellitus (T2D).... 
Diabetic nephropathy | Valsartan | Angiotensin receptor blockers | Proteinuria | Telmisartan | C-REACTIVE PROTEIN | OXIDATIVE STRESS | angiotensin receptor blockers | ENDOTHELIAL DYSFUNCTION | telmisartan | CARDIOVASCULAR OUTCOMES | ALBUMINURIA | proteinuria | RISK MARKER | 8-ISO-PROSTAGLANDIN F2-ALPHA | ASYMMETRIC DIMETHYLARGININE ADMA | BLOOD-PRESSURE | TRANSPLANTATION | MICROALBUMINURIA | UROLOGY & NEPHROLOGY | valsartan | diabetic nephropathy | Benzoates - therapeutic use | Prospective Studies | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Middle Aged | Diabetic Nephropathies - drug therapy | Hypertension - drug therapy | Male | Arginine - analogs & derivatives | Proteinuria - prevention & control | C-Reactive Protein - metabolism | Diabetic Nephropathies - physiopathology | Adult | Female | Blood Pressure - drug effects | Dinoprost - analogs & derivatives | Diabetes Mellitus, Type 2 - complications | Benzimidazoles - therapeutic use | Dinoprost - urine | Double-Blind Method | Valine - analogs & derivatives | Renin-Angiotensin System - physiology | Hypertension - physiopathology | Diabetic Nephropathies - complications | Arginine - blood | Hypertension - complications | Renin-Angiotensin System - drug effects | Tetrazoles - therapeutic use | Valine - therapeutic use | Aged | Diabetes Mellitus, Type 2 - drug therapy | Index Medicus
Journal Article
NATURE MEDICINE, ISSN 1078-8956, 05/2018, Volume 24, Issue 5, pp. 667 - 667
Sphingosine-1-phosphate (S1P) signaling influences bone metabolism, but its therapeutic potential in bone disorders has remained unexplored. We show that... 
MEDICINE, RESEARCH & EXPERIMENTAL | ACTIVATED RECEPTOR-GAMMA | OSTEOBLAST DIFFERENTIATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | ADIPOGENESIS | MESENCHYMAL STEM-CELLS | SPHINGOSINE 1-PHOSPHATE | CELL BIOLOGY | C/EBP-ALPHA | GENE-EXPRESSION | PPAR-GAMMA | MICE | ADIPOSE-TISSUE | Femur - pathology | Adipocytes - drug effects | Femur - diagnostic imaging | Molecular Targeted Therapy | PPAR gamma - metabolism | Obesity - blood | X-Ray Microtomography | Adipose Tissue - metabolism | Anabolic Agents - pharmacology | Osteoporosis - metabolism | Gene Deletion | Osteoprotegerin - blood | Cell Line | Anabolic Agents - therapeutic use | Osteoclasts - pathology | Bone Resorption - blood | Signal Transduction | Osteoblasts - drug effects | Bone Resorption - drug therapy | Organ Size | Aldehyde-Lyases - antagonists & inhibitors | Lysophospholipids - blood | Osteoclasts - metabolism | Mice, Knockout | Obesity - pathology | Bone Resorption - enzymology | Bone Resorption - diagnostic imaging | Osteoblasts - pathology | Sphingosine - analogs & derivatives | Animals | Osteoporosis - pathology | Cell Differentiation - drug effects | Adipocytes - metabolism | Sp7 Transcription Factor - metabolism | Aldehyde-Lyases - metabolism | Sphingosine - blood | Osteoprotegerin - metabolism | Osteoblasts - metabolism | Adipose Tissue - drug effects | Osteoclasts - drug effects | Phosphates | Adipose tissue | Calcium | Population studies | Bone diseases | Osteoprotegerin | Osteoporosis | Body mass index | Bone growth | Calcium (blood) | Biomedical materials | Vitamin D | Ships | LRP5 protein | Biocompatibility | Stiffness | Inhibition | Bone loss | Bone strength | Parathyroid | Ultrasound | Osteopenia | Adipogenesis | Ovariectomy | Medical treatment | Markers | Mechanical properties | Pharmacology | Bone turnover | Metabolism | Osteoclastogenesis | Signaling | Bone mass | Osteoblastogenesis | Body mass | Parathyroid hormone | Body size | Mice | Peroxisome proliferator-activated receptors | Bone | Osteogenesis | Index Medicus
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 07/2004, Volume 44, Issue 2, pp. 362 - 368
We evaluated whether renin-angiotensin system (RAS) blockade attenuates cardiovascular events. Because inflammation and enhanced thrombogenesis are hallmarks... 
coronary artery disease | blood pressure | ACE | enalapril | CAD | cyclooxygenase | angiotensin II type 1 receptor | EUROPA | COX | ANG II | ENAL | angiotensin II | AT1 | angiotensin-converting enzyme | C-REACTIVE PROTEIN | CARDIAC & CARDIOVASCULAR SYSTEMS | ATHEROSCLEROTIC PLAQUES | MYOCARDIAL-INFARCTION | CARDIOVASCULAR EVENTS | HIGH-RISK | ELEVATED LEVELS | TYPE-1 RECEPTOR INHIBITOR | THROMBOXANE BIOSYNTHESIS | UNSTABLE ANGINA | INTERLEUKIN-10 | Double-Blind Method | Humans | Middle Aged | Interleukin-10 - blood | Male | Biomarkers - blood | Dinoprostone - blood | Biphenyl Compounds - therapeutic use | Coronary Artery Disease - blood | Enalapril - therapeutic use | Angiotensin II Type 1 Receptor Blockers | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Interleukin-6 - blood | Coronary Artery Disease - complications | Coronary Artery Disease - pathology | Hypertension - complications | Female | Tetrazoles - therapeutic use | Platelet Aggregation - drug effects | Inflammation - diagnosis | C-Reactive Protein - analysis | Thromboxane A2 - pharmacology | Matrix Metalloproteinase 9 - blood | Enzymes | Evaluation | Care and treatment | Analysis | Cardiac patients | Angiotensin | Cardiology | Coronary heart disease | ACE inhibitors | Heart attacks | Cytokines | Angioplasty | Cardiovascular disease | Patients | Cholesterol | Blood platelets | Coronary vessels | Atherosclerosis | Blood pressure | Nonsteroidal anti-inflammatory drugs | Drug therapy | Acute coronary syndromes | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Hypertension, ISSN 0263-6352, 10/2018, Volume 36 Suppl 3, pp. e9 - e10
OBJECTIVES:Essential hypertension (EH) is a multifactorial disease caused by various environmental and genetic factors. Nitric Oxide (NO) is important for the... 
Journal Article
Clinical Research in Cardiology, ISSN 1861-0684, 3/2013, Volume 102, Issue 3, pp. 193 - 202
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2016, Volume 11, Issue 12, pp. e0168302 - e0168302
Background and Objectives Atherosclerotic changes of arteries are the leading cause for deaths in cardiovascular disease and greatly impair patient's quality... 
HDL | PLASMA | SERUM SPHINGOSINE-1-PHOSPHATE | INFLAMMATION | MULTIDISCIPLINARY SCIENCES | HUMAN PLATELETS | RELEASE | SEPSIS | LYMPHOCYTE EGRESS | CORONARY-ARTERY-DISEASE | SPHINGOSINE 1-PHOSPHATE | Prognosis | Area Under Curve | Lipoproteins, HDL - blood | Humans | Middle Aged | Male | Case-Control Studies | Young Adult | Blood Coagulation | Peripheral Arterial Disease - blood | Aged, 80 and over | Adult | Female | Signal Transduction | Cholesterol, HDL - metabolism | Risk Factors | Lysophospholipids - blood | Atherosclerosis - blood | Regression Analysis | Sphingosine - analogs & derivatives | Sphingosine - blood | ROC Curve | Aged | Carotid Stenosis - blood | Cohort Studies | Care and treatment | Usage | Magnetic resonance imaging | Cholesterol, HDL | Atherosclerosis | Research | Cardiovascular diseases | Peripheral vascular diseases | Heart attack | Risk factors | Phosphates | Heart | Arrhythmia | Medical services | Stenosis | Cardiovascular disease | Blood | Arteries | Sphingosine 1-phosphate | Ethics | Toxicology | Ultrasonic imaging | Vascular diseases | Blood platelets | Surgery | Chronic obstructive pulmonary disease | Pretreatment | Lipoproteins (high density) | Hypertension | Cardiovascular system | Kidneys | Blood & organ donations | Diabetes mellitus | Lung diseases | Mass spectroscopy | Risk analysis | Patients | Cholesterol | Blood flow | Quality of life | Medicine | Signaling | Arteriosclerosis | Coronary vessels | Obstructive lung disease | Conditioned stimulus | Sepsis | Mass spectrometry | Smoking | Kidney transplantation | Index Medicus
Journal Article